Infigratinib is provided as a single dose of minitablets for oral administration
QBGJ398-204
Phase 2 small_molecule active
Quick answer
Infigratinib is provided as a single dose of minitablets for oral administration for Achondroplasia is a Phase 2 program (small_molecule) at BridgeBio Oncology Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BridgeBio Oncology Therapeutics
- Indication
- Achondroplasia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active